

Texas Department of State Health Services

Border
Public Health

Oficina de Salud Pública Fronteriza

Enhanced Respiratory Illness Surveillance Along the West Texas-Mexico Border

Rebecca Basurto-Gonzalez

Border Infectious Disease Epidemiologist

Texas Department of State Health Services

Public Health Region 9/10

Border
Public Health

Salud Pública Fronteriza



Project Objectives

- To maintain year-round Influenza and Influenza-Like Illness (ILI) surveillance activities along the West Texas-Mexico Border areas to:
 - Augment existing ILI surveillance systems in Texas and Federally.
 - Ensure characterization of influenza and other ILIs among border communities and migrant, mobile, or foreign-born populations.
 - Identify and monitor groups at higher risk for severe disease or death.
 - Detect unusual expression of influenza outside of the expected season or novel influenza strains.
 - Contribute to the efforts in public health preparedness, planning, and intervention.





Project Relevance

Addresses the goals for Border Infectious Disease Surveillance (BIDS) set by the Division of Global Migration Health and the Border Health Commission to:

- Improve surveillance of diseases of binational importance
- Assist in the development of strategies for the control of infectious diseases in the border region.
- Application of the Operational Protocol for Binational Communication and Coordination on Disease Notifications and Outbreaks for infectious disease preparedness and response








The West Texas-Mexico Border Region

- Two sets of international sister cities
 - El Paso, TX & Juarez, MX
 - Presidio, TX & Ojinaga, MX
- Two Binational Work Groups
 - Presidio-Ojinaga Border Health Commission
 - Paso del Norte Border Health Commission
- Border Epidemiology Surveillance Team (BEST)
 - Texas, New Mexico, Mexico, Fort Bliss, El Paso Port Health Station, and Ysleta del Sur Pueblo (Tigua Tribe)
- Multi-Agency and multi-disciplinary partners







Involved Parties

- Texas Department of State Health Services Public Health Region 9/10
 - Office of Border Public Health -BIDS Epidemiologist
- Naval Health Research Center
 - Operational Infectious Diseases Border Biosurveillance (NHRC-OID) Team
- Preventative Care Health Services
- Cactus Health Services, Inc.


















Current Sentinel Sites





Enhanced Respiratory Illness Surveillance Project







Project Beginnings

- PHR 9/10 began with Influenza-Like Illness surveillance and sample collection in 2019 with a clinic in Ojinaga, MX and the El Paso Department of Public Health's Laboratory which is part of the Texas Laboratory Response Network.
- We later joined the Naval Health Research Center's
 Operational Infectious Diseases Border Biosurveillance (NHRC-OID) initiative to conduct biosurveillance among U.S.-Mexico Border populations through CDC-BIDS funds.





Current Project Elements

ILI Electronic Reporting

Patient Screening

Sample Collection

Sample Pick Up Sample Packaging and Shipment

Laboratory Testing




Texas Department of State Health Services

Data Reporting Data Analysis and Use



ILI Electronic Reporting

- Each Sentinel site previous week.
- Also asks for count of samples that are ready for pick up.
- Data will be uploaded future.



into ILINet in the near

Marfa

Q3. Please select the Monday of the reporting week for which you wish to report for. 2024-06-03

Q4. *Please enter the patient count of each category listed below.

(If no counts are available, please enter "0")

Total Patient Count seen at your site for any reason during the selected reporting week.	51
ILI Age 0-4	0
ILI Age 5-24	0
ILI Age 25-49	2
ILI Age 50-64	0
ILI Age 65+	0

Q10. *Do you have specimens ready for pickup?

No



Case Definitions & Patient Screening

FRI

- Febrile Respiratory Illness
- Fever ≥ 100.5°F
- Cough or Sore throat

ILI

- Influenza-Like Illness
- Acute Respiratory Infection with:
- Measured fever of ≥ 38°C & Cough &/or sore throat
- Onset within the last 10 days

CLI

- COVID-Like Illness
- Acute Respiratory Infection with:
- Measured fever of ≥ 38°C with two of any of the following symptoms:
 - Chills, cough, sore throat, shortness of breath, headache, difficulty breathing, myalgia, congestion, fatigue, rhinorrhea
- Or Cough with shortness of breath
- Or recent loss of taste &/or smell
- Or Clinical evidence of pneumonia
- Onset within the last 5 days

SARI

- Severe Acute Respiratory Illness
- Acute Respiratory Illness with:
- History of fever ≥ 38°C & cough
- Requires Hospitalization
- Onset within the last 10 days

H5N1 Special Surveillance

Clinical Criteria

Signs and symptoms consistent with acute upper or lower respiratory tract infection **OR** complications of acute respiratory illness without an identified cause

Minimum Symptom Requirements

 Influenza-like-illness (ILI) symptoms (fever plus a cough or sore throat) OR conjunctivitis.



May also present with gastrointestinal symptoms such as diarrhea.

Epidemiologic Criteria

Animal Exposures

Close contact (within 6 feet for a combined total of 15 minutes or more) with animals confirmed to be infected with avian influenza A(H5N1)

OR Close contact with ill appearing animals such as birds or cows, their waste, their unpasteurized milk, saliva, or other body fluids

OR Direct contact with surfaces contaminated with the waste or products (e.g., unpasteurized (raw) milk or saliva) from cattle presumed to be infected with avian influenza A(H5N1).

Food Exposures OR

The individual has consumed unpasteurized milk from an animal confirmed/presu med to be infected with avian influenza A(H5N1).

Human Exposures

Close contact with confirmed case of avian influenza A(H5N1) without the use of respiratory and eye protection

OR Close contact with a Person Under Investigation (PUI) with testing pending without the use of respiratory and eye protection.


*Exposures should be within 10 days of symptom onset



Sample Collection & Storage

- Nasal or NP swab
- Patient must not have already been treated with an antibiotic or an antiviral.
- Sample placed in a Universal Transport Media tube and stored at -80°C to -20°C.
- Samples and Case Report forms do not have patient identifiers and instead use an anonymous labeling system.












Sample Pick Up & Shipping







Sample Laboratory Testing

- Samples are received in San Diego by the NHRC-OID Team and processed.
- Tested via a multi-plex PCR respiratory panel or are rejected and discarded.



OPERATIONAL INFECTIOUS DISEASES

TEST MENU

Laboratory Director: LCDR Paul Graf, PhD CAP # 6928701 CLIP # DOD9215201

RESPIRATORY PANEL

NEOF INATORY PAREE					
VIRUSES	BACTERIA				
 Adenovirus Coronavirus HKU1, NL63, 229E, OC43, SARS CoV-2 Human Bocavirus Human Metapneumovirus Human Rhinovirus/Enterovirus Influenza A A/H3, A/H1 Influenza B Parainfluenza virus PIV 1, 2, 3, 4 Respiratory Syncytial Virus RSV A, RSV B 	➤ Chlamydophila pneumoniae ➤ Mycoplasma pneumoniae				





Results

Operational Infectious Diseases Naval Health Research Center Director: LCDR Paul Graf, PhD, D(ABMM)

Lab Manager: Anne Fraser, MLS(ASCP)^{CM}, CLS anne.c.fraser6.ctr@health.mil

McClelland Rd and Patterson Rd San Diego, CA 92152 Lab Supervisor: Roger Pan, MB(ASCP)^{CM}

Phone: 619.553.9967

roger.w.pan.ctr@health.mil

CAP#: 6928701 CLIP#: DOD9215201

Report ID: 38

Study: FRI Bo.

Presidio County Medical Clinic

Requesting Clinician or Designee:

The NxTag Respiratory Pathogen Panel (RPP) + SARS-CoV-2 assay was used to generate these results. The laboratory is certified under the Clinical Laboratory Improvement Program (CLIP) and College of American Pathologists (CAP) as qualified to perform high complexity clinical laboratory testing. The assay is approved by the CAP and results may be used for clinical purposes. II

The NxTAG RPP + SARS-CoV-2 assay is only for use under the Food and Drug Administration's Emergency Use Authorization.

The NxTAG RPP + SARS-CoV-2 is a multiplex molecular assay for respiratory virus and bacteria detection. The following organism types and subtypes are identified using the NxTAG RPP + SARS-CoV-2:0

-Viral targets: adenovirus, human bocavirus, coronavirus (229E, HKU1, NL63, OC43, and SARS-CoV-2), influenza virus A (H1 and H3), influenza B, hMPV, parainfluenza virus (1, 2, 3, and 4), R5V, A, R5V B, and rithrovirus/enterovirus. □
-Bacterial targets: Chlamydophilis pneumoniae and Mycopiasma pneumoniae. □

.

A result of "Not Detected" or "Negative" indicates that the targeted pathogens were not found to be present above the assay limit of detection.

Specimen: 259687 | Secondary: PR051 | NHRC ID: 971149 | Collection Date: 2024-01-16 | Source: NS

Specimen: 269688 | Secondary: PR052 | NHRC ID: 971150 | Collection Date: 2024-01-16 | Source: NS

No Pathogens Detected

Specimen: 269689 | Secondary: PR053 | NHRC ID: 971151 | Collection Date: 2024-01-16 | Source: NS

Influenza B Detected

Specimen: 269690 | Secondary: PR054 | NHRC ID: 971152 | Collection Date: 2024-01-17 | Source: NS

Influenza B Detected

Specimen: 269691 | Secondary: PR055 | NHRC ID: 971153 | Collection Date: 2024-01-18 | Source: NS

SARS-CoV-2 Detect

Specimen: 269692 | Secondary: PR056 | NHRC ID: 971154 | Collection Date: 2024-01-23 | Source: NS

No Pathogens Detected

Supervisor's Signature: CLAIRE.CALLIN.SH CHAIR SIGNATURE OF THE ACTION O

Date: 2/15/2024

TEXAS
Health and Human
Services

Texas Department of State Health Services

This document may contain information covered under the Privacy Act, 5 USC 552(a), and/or the Health insurance Portability and Accountability Act (PL 104-134) and its various implementing regulations and must be protected in accordance with those provisions. Healthcare information is personal and sensitive and must be treated accordingly. If his correspondence contains healthcare information it is being provided by our after appropriate authorization from the patient or under circumstances that don't require patient authorization. You, the recipient, are obligated to maintain it in a safe, secure and confidential manner. Redisciosure without additional patient consent or as permitted by awis prohibited. Unauthorized redisciosure or fairly to maintain confidentially subjects you to application of appropriate sanction. If you have received this correspondence in error, please notify the sender at once and destroy any copies you have



NHRC CDC BIDS BIOSURVEILLANCE Weekly Report

24 December 2023 - 13 January 2024

Week 52, 2023 - Week 2, 2024

Lab Test Results					
Identification	Site	Pathogens Deteched			
BRD13049	Presidio	Influneza A, Influenza A/H1			
SAR58025	Alpine	Influneza A, Influenza A/H1			
SAR58026	Alpine	Influneza A, Influenza A/H1			
SAR58027	Alpine	SARS-CoV-2			

	r 202		

Fiscal Year to Date Summary								
	Presidio		Alpine		Marfa		Combined	
	Samples	Positivity	Samples	Positivity	Samples	Positivity	Samples	Positivity
Total Samples Tested	17	70.59	27	40.74	10	40.00	54	50.00
Total Samples Positive	12	-	11	-	4	-	27	-
SARS-CoV-2	2	11.76	5	18.52	2	20.00	9	16.67
Rhinovirus/Enterovirus	5	29.41	2	7.41	2	20.00	9	16.67
Influenza A	4	23.53	2	7.41	1	10.00	7	12.96
H1	4	23.53	2	7.41	0	0.00	6	11.11
H3	0	0.00	0	0.00	0	0.00	0	0.00
Influenza B	0	0.00	0	0.00	0	0.00	0	0.00
Bocavirus	0	0.00	0	0.00	0	0.00	0	0.00
Coronavirus	0	0.00	0	0.00	0	0.00	0	0.00
OC43	0	0.00	0	0.00	0	0.00	0	0.00
229E	0	0.00	0	0.00	0	0.00	0	0.00
HKU1	0	0.00	0	0.00	0	0.00	0	0.00
NL63	0	0.00	0	0.00	0	0.00	0	0.00
Parainfluenza virus	0	0.00	0	0.00	0	0.00	0	0.00
PIV-1	0	0.00	0	0.00	0	0.00	0	0.00
PIV-2	0	0.00	0	0.00	0	0.00	0	0.00
PIV-3	0	0.00	0	0.00	0	0.00	0	0.00
PIV-4	0	0.00	0	0.00	0	0.00	0	0.00
Respiratory Syncytial Virus	1	5.88	2	7.41	0	0.00	3	5.56
RSV A	1	5.88	1	3.70	0	0.00	2	3.70
RSV B	0	0.00	1	3.70	0	0.00	1	1.85
Human Metapneumovirus	0	0.00	0	0.00	0	0.00	0	0.00
Adenovirus	0	0.00	0	0.00	0	0.00	0	0.00
Chlamydia pneumoniae	0	0.00	0	0.00	0	0.00	0	0.00
Mycoplasma pneumoniae	0	0.00	0	0.00	0	0.00	0	0.00
Negative	5	29.41	16	59.26	6	60.00	27	50.00

Abbreviations:

RSV (respiratory syncytial virus) hMPV (human metapneumovirus)

hMPV (human metapneumov RUO (research use only)

.....

"/" indicates "and/or"

";" indicates "and" (coinfection)

Sites:

Presidio (Presidio County Medical Clinic) Alpine (Alpine Family Health Services) Marfa (Marfa Community Health Clinic)

Data









Data Storage & Analysis









Respiratory Panel Data – 2023-2024 Flu Season




Identified Organisms




Major Respiratory Illness Categories




Flu Positives - 2023-2024 Flu Season







Influenza Results vs Vaccination Status



Flu Test Results vs Travel History



INFLUENZA VACCINATION RATES






Border Influenza Surveillance Network Report

- A respiratory illnesses data report for counties along the West Texas-Mexico Border.
- Distributed to local, regional, state, and federal programs and other non-Texas BIDS partners.
- Other data comes from ESSENCE Syndromic Surveillance, Texas DSHS dashboards, ILINet, and FluView





Future Direction

Expansion Regionally and in Texas







Next Steps

- Ojinaga, Mexico clinics invitation into the project.
 - Orientation and Training scheduled for August 2024
 - All CDC import permits have been acquired
 - NHRC is working on translation of documents.
- Discussions are being held with the local health authority in El Paso, TX.
- Future Expansion regionally
 - Culberson & Hudspeth County
- Invitation to the Ysleta del Sur Pueblo to participate in the project as well.
- Potential state expansion into PHRs 8 & 11





Resources

- Torres, D. (2020) BIDS/NHRC Collaboration for Enhanced Virologic, COVID-like Illness (CLI), and Severe Acute Respiratory Infection (SARI) Surveillance Protocol.
- Torres, D. (2020) Enhanced Influenza-Like Illness (ILI) / COVID-Like Illness (CLI) Surveillance Protocol adaptation for Texas Department of State Health Services Public Health Region 9/10 to include specimens from Ojinaga, Chihuahua, Mexico.
- United States-Mexico Binational Technical Work Group. (2015)
 Operational Protocol for U.S.-Mexico Binational Communication and Coordination on Disease Notifications and Outbreaks.
- U.S. Department of Health and Human Services (HHS) and the Secretariat of Health of Mexico. (2012) Technical Guidelines for United States—Mexico Coordination on Public Health Events of Mutual Interest.



Thank you! iGracias!

obph@dshs.texas.gov

Border
Public Health

Salud Pública Fronteriza